[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100421623":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":21,"studyPopulation":13,"armGroups":22,"interventions":37,"overallOfficials":45,"centralContacts":49,"locations":58,"responsibleParty":78,"collaborators":13,"id":80,"slug":13,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":13,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":13,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":61,"whyStopped":13,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumors","Assessing incidence of side effects and primary clinical response of the intra-tumor injection of DEB in advanced solid cancers, including CR, PR, SD, and PD.","up to 36 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":17,"primaryPurpose":18,"observationalModel":13,"timePerspective":13,"maskingInfo":19},"NON_RANDOMIZED","PARALLEL","Drug-eluting beads loaded with various drugs including IL2, kytruda, imfinzi, yevoy, bevacizumag, or\u002Fand ramucirumab, doxorubicin\u002Fidarubicin are injected into solid tumors under CT guidance according to appropriate treatment strategy, once per 3-6 weeks, and the safety and efficacy will be evaluated by guidelines.","TREATMENT",{"masking":20,"maskingDescription":13,"whoMasked":13},"NONE","Drug-eluting microspheres such as DC-beads will be loaded with IL2, PD1\u002FPDL1\u002FCTLA4 antibody, or \u002Fand VEGF\u002FVEGFR antibody with or without doxorubicin\u002Fidarubicin for various time and injected into tumors under CT guidance. Side effects and treatment efficacy after injection of drug-eluting microspheres into malignant tumors will be assessed according to RICEST1.1 standard.",[23,29,33],{"label":24,"type":25,"description":26,"interventionNames":27},"Group 1: DC-Beads loading with Chemodrug\u002FIL2\u002FPD1\u002FCTLA4 antibodies","EXPERIMENTAL","Intra-tumor injection of above drugs for patients with previous treatment with PDL1 antibody and relapsed.",[28],"Drug: Injection of drug-eluting microspheres with multiple drugs into solid tumors",{"label":30,"type":25,"description":31,"interventionNames":32},"Group 2: DC-Beads loading with Chemodrug\u002FIL2\u002FPDL1\u002FCTLA4 antibodies","Intra-tumor injection of above drugs for patients with previous treatment with PD1 antibody and relapsed.",[28],{"label":34,"type":25,"description":35,"interventionNames":36},"Group 3: DC-Beads loading with Chemodrug\u002FIL2\u002FPD1\u002FPDL1\u002FCTLA4 antibodies","Intra-tumor injection of above drugs for patients with previous heavily treated with PD1\u002FPDL1\u002FCTLA4 antibodies and relapsed.",[28],[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","Injection of drug-eluting microspheres with multiple drugs into solid tumors","Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor",[24,30,34],[44],"Checkpoint inhibitor (CPI) such as Keytruda plus chemodrug",[46],{"name":47,"affiliation":5,"role":48},"Zhenfeng Zhang, MD, PhD","PRINCIPAL_INVESTIGATOR",[50,55],{"name":51,"role":52,"phone":53,"phoneExt":13,"email":54},"Bingjia He, MD","CONTACT","+862039195965","464677938@qq.com",{"name":47,"role":52,"phone":56,"phoneExt":13,"email":57},"+862039195966","zhangzhf@gzhmu.edu.cn",[59],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"The Second Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510260","China","CN",{"type":68,"coordinates":69},"Point",[70,71],113.25,23.11667,{"lat":71,"lon":70},[74,77],{"name":75,"role":52,"phone":76,"phoneExt":13,"email":54},"BINGJIA HE, MD","13560199303",{"name":47,"role":52,"phone":56,"phoneExt":13,"email":57},{"type":79,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100421623",false,"NCT04770207","Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs","Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and\u002For IL2 for Treatment of Advanced Solid Tumors","Inclusion Criteria:\n\n* Solid advanced malignant tumors\n* Age between18 and 99 years\n* Life expectancy is greater than three months\n\nExclusion Criteria:\n\n* Benign tumor\n* Life expectancy is less than three months\n* Serious medical comorbidity\n* Others","ALL","18 Years","99 Years",{"count":90,"type":91},100,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and\u002For protein drugs into advanced solid tumors.",[97,98],"Hepatocellular Carcinoma","Solid Tumor, Adult",[100,101,102,103,104,105],"Hepatocellular Carcinoma; Lung Cancer; Solid Tumors","Drug-eluting Beads","IL2; Kytruda; Opdivo; Imfinza; Atezolizumab; Ipilimumab;","Treprizolizumab; Tirelizumab; Carellizumab; Sintilimab;","Sugemalimab；Adebrelimab；Envafolimab；Cadonilimab；","Bevacizumab; Ramucirumab","2024-08-19",{"date":108,"type":109},"2024-08-21","ACTUAL",{"date":111,"type":109},"2020-11-01",{"date":113,"type":91},"2035-11-01",{"name":5,"class":6},1]